Management of secondary hyperparathyroidism: the gap between diagnosis and treatment. The Renal Osteodystrophy Multicenter Enquiry.
In mild secondary hyperparathyroidism, small daily doses of oral calcitriol represent the physiological form of replacement of this hormone, but in moderate or severe cases, higher doses of calcitriol are needed to suppress parathyroid gland overactivity. Unfortunately, in chronic renal failure, these 2 different forms of calcitriol prescription are not always adequately selected. This review will focus on the current use of calcitriol in renal failure. It includes data from a recent multicenter trial carried out in Spain in which data was gathered from dialysis patients. This trial was designed to determine the current approach to the prevention, diagnosis, and treatment of renal osteodystrophy, with a special emphasis on the gap found between diagnosis and treatment of secondary hyperparathyroidism. Our main goal should be to achieve an adequate and early management of secondary hyperparathyroidism to decrease the number of patients suffering from irreversible enlargement of the parathyroid glands.
Díaz-Corte
C
C
Bone and Mineral Research Unit, Instituto Reina Sofía, Hospital Central de Asturias, Oviedo, Spain.
Cannata-Andía
J B
JB
D002117:Calcitriol / Q000627:therapeutic use*; D002118:Calcium / Q000097:blood; D006801:Humans; D006962:Hyperparathyroidism, Secondary / Q000097:blood / Q000175:diagnosis* / Q000188:drug therapy* / Q000209:etiology; D007676:Kidney Failure, Chronic / Q000150:complications; D015337:Multicenter Studies as Topic; D010281:Parathyroid Hormone / Q000097:blood; D010530:Peritoneal Dialysis; D006435:Renal Dialysis; D013030:Spain
D010281:Parathyroid Hormone; D002117:Calcitriol; D002118:Calcium